secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0001628280-22-027472
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion Q3 2022 product rev $14.0M (+28% Y/Y); net loss $55.1M; CLEAR Outcomes trial finished
--------------------------------------------------------------------------------

- U.S. net product revenue $14.0M (up 28% YoY); total revenue $19.0M (up 32% YoY).
- Net loss $55.1M ($0.81 diluted EPS) vs $69.4M loss ($2.62 EPS) in Q3 2021.
- CLEAR Outcomes trial achieved last patient last visit in Oct 2022; topline results expected Jan 2023.
- SG&A down 36% YoY to $25.0M; R&D up 15% to $29.1M; cash $239.3M (down $70M from Dec 2021).
- Reaffirmed FY2022 OpEx guidance: total $220-240M including $25M stock-based comp.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828022027472/0001628280-22-027472-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828022027472/espr-20221101.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-027472

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer